We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Aortech International Plc | LSE:AOR | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 126.50 | 123.00 | 130.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
02/10/2013 08:44 | Harrogate. I believe that until the deal with Syncardia is settled and announced the directors may be precluded from buying shares. I agree that their purchases would offer a significant amount of confidence behind the deal. Let's see ;0) I agree with you; a Broker/Analyst note would be great. No One has really done that in the past, so if they do now, that will also add confidence. Some guidance will be good! It is my understanding that the running costs are significantly down and will continue to fall over the next 6 months. There is no doubt that this deal is a company saver. The share price will react to the settlement with Syncardia and any deals as they happen. | gac141 | |
02/10/2013 08:27 | Thanks for that George. We are now in the situation that we don't really know what the numbers will look like and may not do for a good while. We are relying on the directors believing that this is a great deal and will be very good for AOR. I am happy to do that given the efforts they have made but at less than £4m market cap if they really believe it they might want to demonstrate that with a few share purchases. That I think would put some real substance behind this deal and what it means for the future. And maybe sort some broker coverage out so we can get more visibility of what it means. I would also like to know the current monthly run rate on overheads and if that is appropriate for an IP licensing company | harrogate | |
02/10/2013 07:01 | AorTech's future looks more secure after licence deal with US company Simon Bain Business Correspondent/Person Wednesday 2 October 2013 Aortech, the heart valve developer formerly based in Lanarkshire, has signed a licence deal with a US company that should underpin its future after being saved from collapse last year. Biomerics of Salt Lake City will manufacture and distribute its patented Elast-Eon and ECSil materials and supply the polymer requirements of AorTech's current licensees. It follows AorTech's exit from manufacturing and its adoption of a new strategy to "exploit the value of the company's IP, patents and knowhow without incurring the further substantial expenditure required to maintain and develop manufacturing facilities, product development expertise and sales and marketing resources". Chairman Bill Brown, the former Edinburgh-based fund manager, said: "This is the most important deal AorTech has done." He said AorTech's size and scale had made it impossible to get its material into major medical device companies, who were taking it "despite AorTech". The company was rescued when emergency bondholders earned a 100% return and a 15% stake in the company for enabling AorTech to defend itself in US litigation last year. Mr Brown said: "It is now a business that if everything goes to plan will take the material into new areas....we have got the potential to make more margin from any sales without having any cost, and are close to being a pure IP company." He said the heart valve project had potential "at some point - it has been one piece at a time". Frank Maguire, chief executive, said: "This relationship with Biomerics provides for large volume manufacturing economies of scale.... a deep pool of talented application engineering resources facilitating new business development, and access to new customers and markets for AorTech polymers." Aortech shares, which had climbed to 370p in February 2012 before crashing to 55p in October, rose 4p to 81.5p, valuing AorTech at just under £4m. | gac141 | |
01/10/2013 16:21 | I believe the the deal was finalised late last night US time. The directors are in this for themselves and shareholders. As a shareholder I have experienced this ever since Bill and Roy came on Board. | gac141 | |
01/10/2013 15:54 | As I said earlier a move in the right direction. With no numbers available to shareholders on the deal or possible future revenue streams. I will carry on saying this company is being run by the directors for the directors. On a final note why was the rns not released before the market opens. | cocker | |
01/10/2013 14:49 | "BY GEORGE YOU'VE GOT IT" Just a scratch on the surface. Time to buy! | 1prophet | |
01/10/2013 14:15 | I think some have not grasped how good a situation this is for us and our partner. This could be a hugely profitable business.With minimal overheads. | gac141 | |
01/10/2013 13:36 | It's clearly very good news. You still need patience here but we've never had this opportunity to go out and freely market Elast-Eon™ and ECSil™ before, so hold on. | 1400 | |
01/10/2013 11:03 | There u have it!! says all you need to know about this company and its share price. SP is down on the RNS on what everyone has posted today as good news. | papillon88 | |
01/10/2013 09:43 | Yes looks like good news. All we need now is some numbers. | tadders2 | |
01/10/2013 09:02 | This looks like good news. It is what we needed to do to get our costs in line. The niggle I have is the terms of the deal. There is no mention of any upfront payment to AOR for this and so we will be dependent for any growth on the Biomerics guys selling our products, unless there are minimum royalties which again were not mentioned. If I look at the website they look to have similar products ( to a layman anyway) and I have had some experience of a large company taking on the Technology of a smaller company with no minimum royalties and effectively just supplying existing customers but making little effort to market it since the sales team knew and liked their existing products. No complaints from me though and I am sure they did the best deal they could. | harrogate | |
01/10/2013 08:36 | One bit of good news in how long !. A step in the right direction for sure but lets not get carried away. | cocker | |
01/10/2013 08:34 | This came from side field. It must secure the business going forward. | way2000 | |
01/10/2013 08:27 | Wow that is very good news indeed. We are going to be the company we always should have been! Well done the directors. Maybe those that gave criticised the board will come forward and congratulate them. | gac141 | |
30/9/2013 17:43 | No Comment! On a serious note.. I cannot remember when we had so many trades going though on one day..must be at least 18 months. Intriguing..... | gac141 | |
30/9/2013 15:33 | Shareholders faith will be rewarded. Keep true to your life's mission. | 1prophet | |
30/9/2013 13:50 | Interesting trades today! | gac141 | |
27/9/2013 14:56 | Long may we see the color Blue. Sit tight up from here. | 1prophet | |
27/9/2013 12:32 | My broker thinks some good news may be around the corner. Pretty soon by the sounds of it. He knows someone who went to the AGM. Been very disappointed in this company so any good news will be more than welcome. | way2000 | |
27/9/2013 12:07 | Interesting!! | papillon88 | |
27/9/2013 10:14 | One on 74 and 2 on 79 now. | gac141 | |
27/9/2013 09:02 | Only one left on 74 other two on 77 and 79 now. | gac141 | |
27/9/2013 08:59 | Maybe ..but not in the AGM announcment that has come out that is for sure. I did have an inkling that they might not all be sells But not all buys since surely the price would have gone up a long way !!! | harrogate |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions